FX.co ★ Natera - Harkening Back To Its Heyday

Shares of Natera Inc. (NTRA) have experienced a significant resurgence, surpassing the $120 benchmark, reminiscent of their historical peak performance.

Natera Inc. specializes in diagnostics, offering cell-free DNA (cfDNA) testing with a focus on oncology, women's health, and organ health. cfDNA encompasses small DNA fragments released from normal and diseased cells into the bloodstream. This advanced testing is invaluable for identifying genomic variants linked to hereditary or genetic disorders, cancer detection and characterization, and monitoring cancer therapies.

The company's product portfolio includes the Panorama non-invasive prenatal test (NIPT), Horizon Carrier Screening (HCS) test, Spectrum Preimplantation Genetics, Anora miscarriage test, Vistara single-gene NIPT, Empower hereditary cancer screening test, Signatera molecular residual disease test for oncology applications, and Prospera organ transplant assessment tests.

In the second quarter of 2024, Natera exceeded its financial expectations, showcasing robust performance in volume, revenue, and gross margin.

### Q2 Recap

- **Revenue**: $413.4 million, a 58.1% increase from $261.4 million in Q2 2023, driven by higher test volumes and improved average selling prices.

- **Testing Volume**: Approximately 760,300 tests processed, compared to 617,200 in the same quarter the previous year.

- **Gross Profit**: Increased to $243.2 million from $118.3 million, with gross margins of 58.8% and 45.2%, respectively.

- **Net Loss**: Reduced to $37.5 million or $0.30 per share, down from $110.8 million or $0.97 per share in Q2 2023.

- **Financial Position**: As of June 30, 2024, the company had approximately $887.1 million in cash, cash equivalents, short-term investments, and restricted cash.

### The Path Forward

Looking ahead, Natera projects total revenue for 2024 to range between $1.49 billion and $1.52 billion, with a gross margin approximately between 54% and 56%. In 2023, total revenue stood at $1.08 billion with a gross margin of 45.5%. This marks the second instance of the company revising its revenue and gross margin guidance upward for 2024.

Natera's initial public offering on the Nasdaq Global Select Market (ticker: NTRA) occurred on July 1, 2015, at an initial price of $18.00 per share.

We previously highlighted Natera in our report "Natera - Will Heydays Be Back?" on December 21, 2022, when the stock was trading around $41.75.

With NTRA closing at $122.61 in yesterday's trading, it is clear that the stock has regained its past grandeur. This raises the critical question: Is there potential for further growth, or has Natera already reached its zenith?